TNGX
Tango Therapeutics, Inc.
$20.24
-1.38
(-6.38%)
Mkt Cap
2.35B
Volume
1,596,911
52W Range
1.905-28.41
Sector
Healthcare
Beta
1.22
EPS (TTM)
-0.83
P/E Ratio
-10.13
Revenue (TTM)
56.99M
Rev Growth (5Y)
+52.1%
EPS Growth (5Y)
N/A
Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Net Income | (101.59M) | (130.30M) | (101.74M) | (108.18M) | (58.23M) | (51.97M) | (14.10M) |
| EPS | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Free Cash Flow | (139.93M) | (132.25M) | (119.51M) | (116.77M) | (61.36M) | 68.97M | (26.62M) |
| FCF / Share | -1.20 | -1.21 | -1.26 | -1.33 | -0.99 | 0.79 | -0.30 |
| Operating CF | (138.89M) | (131.50M) | (117.98M) | (109.08M) | (59.53M) | 70.07M | (24.80M) |
| Total Assets | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M | 207.25M | 55.76M |
| Total Debt | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M | 7.88M | 8.54M |
| Cash & Equiv | 112.28M | 69.53M | 66.39M | 59.97M | 142.75M | 28.38M | 22.89M |
| Book Value | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M | 38.60M | 7.91M |
| Return on Equity | -0.29 | -0.65 | -0.40 | -0.43 | -0.17 | -1.35 | -1.78 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 53.81M | 3.18M | 5.39M | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M | 10.73M | 14.60M |
| Net Income | (45.51M) | (38.75M) | 15.88M | (38.85M) | (39.88M) | (37.67M) | (29.17M) | (25.55M) | (37.91M) | (30.76M) | (22.26M) | (20.71M) |
| EPS | -0.32 | -0.30 | 0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| Free Cash Flow | (44.36M) | (29.94M) | (31.10M) | (37.14M) | (41.75M) | (36.77M) | (33.51M) | (23.93M) | (38.05M) | (27.69M) | (31.15M) | (25.14M) |
| FCF / Share | -0.31 | -0.26 | -0.28 | -0.34 | -0.38 | -0.34 | -0.31 | -0.22 | -0.35 | -0.29 | -0.32 | -0.28 |
| Operating CF | (44.36M) | (29.72M) | (30.95M) | (36.52M) | (41.70M) | (36.65M) | (33.39M) | (23.61M) | (37.86M) | (27.47M) | (31.14M) | (24.47M) |
| Total Assets | 435.79M | 398.69M | 210.14M | 237.89M | 274.31M | 316.49M | 352.42M | 381.45M | 406.22M | 402.57M | 428.19M | 379.33M |
| Total Debt | 32.79M | 33.57M | 34.76M | 35.01M | 36.95M | 36.49M | 37.63M | 37.84M | 38.23M | 38.92M | 39.51M | 39.89M |
| Cash & Equiv | 157.83M | 112.28M | 58.34M | 39.27M | 58.43M | 69.53M | 53.15M | 51.57M | 61.16M | 66.39M | 58.53M | 66.05M |
| Book Value | 391.51M | 346.18M | 160.03M | 134.95M | 166.76M | 199.52M | 229.17M | 247.67M | 264.45M | 253.11M | 276.60M | 212.94M |
| Return on Equity | -0.12 | -0.11 | 0.10 | -0.29 | -0.24 | -0.19 | -0.13 | -0.10 | -0.14 | -0.12 | -0.08 | -0.10 |
TNGX News
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Massachusetts Financial Services Co. MA Acquires New Shares in Tango Therapeutics, Inc. $TNGX
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $961,500.00 in Stock
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge
Adam Crystal Sells 12,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX